HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/4/H1655    most recent 01072.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Szmitko, P. E. Articles by Verma, S. Search for Related Content PubMed PubMed Citation Articles by Szmitko, P. E. Articles by Verma, S.

INVITED REVIEW

Adiponectin and cardiovascular disease: state of the art?

¹Department of General Internal Medicine, and Divisions of ²Cardiac Surgery and ³Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

The cardiometabolic syndrome, associated with increased cardiovascular disease risk in the industrialized world, is estimated to affect one in four adults. Although the mechanisms linking obesity and cardiovascular disease remain unclear, research continues to unravel the molecular pathways behind this pandemic. Adipose tissue has emerged as a metabolically active participant in mediating vascular complications, serving as an active endocrine and paracrine organ secreting adipokines, which participate in diverse metabolic processes. Among these adipokines is adiponectin, which seems to possess antiatherogenic and anti-inflammatory effects and may be protective against cardiovascular disease development. The current review describes the pathophysiology of adiponectin in atherosclerotic disease.

atherosclerosis; adipokines; cardiometabolic syndrome

This article has been cited by other articles:

				W. Galal, Y. R. B. M. van Gestel, S. E. Hoeks, D. D. Sin, T. A. Winkel, J. J. Bax, H. Verhagen, A. M. M. Awara, J. Klein, R. T. van Domburg, et al. The Obesity Paradox in Patients With Peripheral Arterial Disease Chest, November 1, 2008; 134(5): 925 - 930. [Abstract] [Full Text] [PDF]

				C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]